March 21, 2023
Amgen can't escape a lawsuit accusing it of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market, a Delaware federal judge has ruled.
February 13, 2023
A magistrate judge recommended a Delaware federal court deny Amgen's attempts to toss or delay Regeneron's claims that Amgen Inc. used a bundling scheme to boost its cholesterol medication sales and said additional documents Amgen submitted should be ignored.
August 09, 2022
Pharmaceutical giant Amgen asked a Delaware federal court to throw out a suit from competitor Regeneron alleging that Amgen used a bundling scheme to boost its own cholesterol medication sales while ruining the market for Regeneron's competing product.
May 31, 2022
Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.